Status:
COMPLETED
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
Lead Sponsor:
Duke University
Conditions:
Diffuse Large B-cell Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radi...
Eligibility Criteria
Inclusion
- Histologic documentation of diffuse large B-cell lymphoma, or any of its variants as defined in the WHO classification
- Completion of at least 4 cycles of a rituximab-containing, anthracycline-based combination chemotherapy
- Negative post-chemotherapy (or interim) PET scan
- Absolute neutrophil count greater than 1500 and platelet count greater than 40,000
- Negative pregnancy test in women of child-bearing potential
- For patients with HIV/AIDS, the following must be true:
- The patient is compliant on combination anti-retroviral therapy (CART)
- The patient has CD4 count ≥ 200 at time of diagnosis
Exclusion
- Any contraindications to irradiation
- Primary CNS lymphoma
- HIV/AIDS
Key Trial Info
Start Date :
September 20 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 4 2019
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01186978
Start Date
September 20 2010
End Date
June 4 2019
Last Update
June 2 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Durham Regional Hospital
Durham, North Carolina, United States, 27704
2
Duke University Medical Center
Durham, North Carolina, United States, 27710
3
Duke Raleigh Hospital
Raleigh, North Carolina, United States, 27609